158 related articles for article (PubMed ID: 36249820)
41. Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis.
Wu R; Dong S; Cai FF; Chen XL; Yang MD; Liu P; Su SB
Molecules; 2019 Jan; 24(2):. PubMed ID: 30669350
[TBL] [Abstract][Full Text] [Related]
42. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim.
Xu HY; Ren JH; Su Y; Ren F; Zhou YJ; Jiang H; Cheng ST; Zhang CR; Chen J
J Ethnopharmacol; 2020 Jul; 257():112787. PubMed ID: 32224198
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous determination of eight analytes of Fuzheng Huayu recipe in beagle dog plasma by UHPLC-Q/exactive Orbitrap HRMS and its application to toxicokinetics.
Wang YL; Yang MJ; Li RS; Hu YQ; Pan YF; Yang T
Biomed Chromatogr; 2022 Apr; 36(4):e5329. PubMed ID: 34997600
[TBL] [Abstract][Full Text] [Related]
44. Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis.
Chen Q; Wu F; Wang M; Dong S; Liu Y; Lu Y; Song Y; Zhou Q; Liu P; Luo Y; Su S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271613
[TBL] [Abstract][Full Text] [Related]
45. Comparative pharmacokinetic and tissue distribution profiles of four major bioactive components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Yang T; Liu S; Wang CH; Tao YY; Zhou H; Liu CH
J Pharm Biomed Anal; 2015 Oct; 114():152-8. PubMed ID: 26048667
[TBL] [Abstract][Full Text] [Related]
46. [Effects of Chinese herbal medicine Fuzheng Huayu recipe and its components against hepatocyte apoptosis in mice with hepatic injury].
Zhou T; Yan XC; Chen Q; Tao YY; Hu YY; Liu P; Liu CH
Zhong Xi Yi Jie He Xue Bao; 2011 Jan; 9(1):57-63. PubMed ID: 21227034
[TBL] [Abstract][Full Text] [Related]
47. [Clinical study of yiqi huoxue recipe in the treatment of liver fibrosis of chronic viral hepatitis].
Cui LY; Zhang XX; Cui P; Li WC; Zhang YG; Wang RQ; Zhao SX; Ren WG; Kong LL; Han F; Yuan XW; Liu LD; Zhang Y; Zhang QS; Kong L; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2020 May; 28(5):403-409. PubMed ID: 32536056
[No Abstract] [Full Text] [Related]
48. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
[TBL] [Abstract][Full Text] [Related]
49. [Effect of fuzheng huayu recipe and huangqi tang on DMN-induced experimental liver cirrhosis in rats].
Wang L; Yan X; Zeng Z; Lv J; Liu P; Liu C
Zhongguo Zhong Yao Za Zhi; 2010 Jul; 35(13):1740-4. PubMed ID: 20862970
[TBL] [Abstract][Full Text] [Related]
50. Metabolic mechanisms of Fuzheng-Huayu formula against liver fibrosis in rats.
Hu XQ; Song YN; Wu R; Cai FF; Zhang Y; Peng JH; Hu YY; Su SB
J Ethnopharmacol; 2019 Jun; 238():111888. PubMed ID: 31004725
[TBL] [Abstract][Full Text] [Related]
51. Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion.
Yang HY; Zheng NQ; Li DM; Gu L; Peng XM
Virol J; 2014 Sep; 11():165. PubMed ID: 25224377
[TBL] [Abstract][Full Text] [Related]
52. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
[TBL] [Abstract][Full Text] [Related]
53. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
Wu Y; Wen J; Tang G; Zhang J; Xin J
J Infect; 2021 Nov; 83(5):594-600. PubMed ID: 34474058
[TBL] [Abstract][Full Text] [Related]
54. Seropharmalogical effects of Fuzheng Huayu decoction on rat Ito cell morphology and function in culture.
Liu CH; Liu C; Liu P; Xu LM
World J Gastroenterol; 1997 Dec; 3(4):263-5. PubMed ID: 27053890
[TBL] [Abstract][Full Text] [Related]
55. [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B].
Liu P; Hu YY; Liu C; Xu LM; Liu CH; Sun KW; Hu DC; Yin YK; Zhou XQ; Wan MB; Cai X; Zhang ZQ; Ye J; Tang BZ; He J
Zhong Xi Yi Jie He Xue Bao; 2003 Jul; 1(2):89-98, 102. PubMed ID: 15339577
[TBL] [Abstract][Full Text] [Related]
56. The decline of HBV RNA associated with HBeAg seroconversion and double-negative HBV DNA and RNA in chronic hepatitis B patients who received entecavir therapy: a 10-year retrospective cohort study.
Ye F; Zhao W; Yang X; Zhang X; An X; Zhu R; Chen Y; Liu X; Li J; Li K; Zheng J; Lin S; Shi L
Ann Transl Med; 2022 Aug; 10(16):897. PubMed ID: 36110993
[TBL] [Abstract][Full Text] [Related]
57. Chinese herbal extract Su-duxing had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis B virus (HBV) in vitro and effectively suppressed HBV replication in mouse model.
Liu Y; Yao W; Si L; Hou J; Wang J; Xu Z; Li W; Chen J; Li R; Li P; Bo L; Xiao X; Lan J; Xu D
Antiviral Res; 2018 Jul; 155():39-47. PubMed ID: 29702120
[TBL] [Abstract][Full Text] [Related]
58. [Fuzheng Huayu recipe promotes the fenestration of capillarization in liver sinusoidal endothelial cells].
Xie Z; Yu Y; Feng D; Xie J; Liu F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 40(7):723-8. PubMed ID: 26267683
[TBL] [Abstract][Full Text] [Related]
59. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
[TBL] [Abstract][Full Text] [Related]
60. Curative Effects of Fuzheng Huayu on Liver Fibrosis and Cirrhosis: A Meta-Analysis.
Dong S; Chen QL; Su SB
Evid Based Complement Alternat Med; 2015; 2015():125659. PubMed ID: 26221168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
